top of page
Research Articles and Other Literature
Article | Date Published | Author(s) | Link to Article |
|---|---|---|---|
The 2016 Heroin Signature Program Report: DEA Intelligence Report Copy | 2018 | DEA | https://www.dea.gov/sites/default/files/2018-10/Heroin%20Signature%20Report%20FINAL.pdf |
Prescription Opioid Exposures Among Children and Adolescents in the United States: 2000–2015 | 2017 | Jakob D. Allen, Marcel J. Casavant, MD, Henry A. Spiller, MS, D.ABAT, Thiphalak Chounthirath, MS, Nichole L. Hodges, PhD, Gary A. Smith, MD, DrPH | https://pediatrics.aappublications.org/content/pediatrics/139/4/e20163382.full.pdf |
Prescription opioid use and misuse among adolescents and young adults in the United States: A national survey study | 2019 | Joel D. Hudgins, John J. Porter, Michael C. Monuteaux, Florence T. Bourgeois | https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002922 |
Racial/Ethnic and Age Group Differences in Opioid and Synthetic Opioid–Involved Overdose Deaths Among Adults Aged ≥18 Years in Metropolitan Areas — United States, 2015–2017 | 2019 | Kumiko M. Lippold, PhD; Christopher M. Jones, PharmD; Emily O’Malley Olsen, PhD; Brett P. Giroir, MD | https://www.cdc.gov/mmwr/volumes/68/wr/mm6843a3.htm |
Rapid widespread distribution of intranasal naloxone for overdose prevention | 2017 | Desiree Madah-Amiri, Thomas Clausen, Philipp Lobmaier | https://www.sciencedirect.com/science/article/pii/S0376871617300315?via%3Dihub |
QuickStats: Rates of Drug Overdose Deaths Involving Heroin,* by Selected Age Groups — United States, 2006–2015 | 2017 | National Center for Health Statistics | https://www.cdc.gov/mmwr/volumes/65/wr/pdfs/mm6552a12.pdf |
Report on the Risk Assessment of Acryloylfentanyl | 2017 | European Monitoring Centre for Drugs and Drug Addiction | https://www.emcdda.europa.eu/publications/risk-assessments/acryloylfentanyl_en |
Report on the Risk Assessment of Furanylfentanyl | 2017 | European Monitoring Centre for Drugs and Drug Addiction | https://www.emcdda.europa.eu/publications/risk-assessments/furanylfentanyl_en |
Sold as Heroin: Perceptions and Use of an Evolving Drug in Baltimore, MD | 2017 | Sarah G. Mars, Ph.D; Jeff Ondocsin, M.A.; Daniel Ciccarone, MD, MPH | https://www.tandfonline.com/doi/abs/10.1080/02791072.2017.1394508?journalCode=ujpd20 |
State and Substate Estimates of Nonmedical Use of Prescription Pain Relievers | 2017 | Rachel N. Lipari, Ph.D., Struther L. Van Horn, M.A., Arthur Hughes, M.S. and, Matthew Williams, Ph.D. | https://www.samhsa.gov/data/sites/default/files/report_3187/ShortReport-3187.html |
The 2015 Heroin Signature
Program Report: DEA Intelligence Report | 2017 | DEA | https://www.dea.gov/sites/default/files/2018-07/DEA-DCW-DIR-032-17%20The%202015%20Heroin%20Signature%20Report.pdf |
The Role of Science in Addressing the Opioid Crisis | 2017 | Nora D. Volkow, M.D., and Francis S. Collins, M.D., Ph.D. | https://www.nejm.org/doi/full/10.1056/NEJMsr1706626 |
Page 1 of 1
bottom of page